(5-ethyl-2-hydroxy-phenyl)-pyridin-2-yl-methanone | 108294-98-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (5-ethyl-2-hydroxy-phenyl)-pyridin-2-yl-methanone
• 英文别名: (5-ethyl-2-hydroxyphenyl)-pyridin-2-ylmethanone
• CAS: 108294-98-0
• 化学式: C₁₄H₁₃NO₂
• 分子量: 227.263
• InChiKey: WMSMPRGPTJTMMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-3-[4-(3-methanesulfonyloxy-butoxy)-2-methyl-phenyl]-propionic acid methyl ester 、 (5-ethyl-2-hydroxy-phenyl)-pyridin-2-yl-methanone 在 caesium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 17.0h， 以25%的产率得到(R)-3-(4-{3-[4-ethyl-2-(pyridine-2-carbonyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid methyl ester
  参考文献：
  名称：

  [EN] PPAR MODULATORS
  [FR] MODULATEURS DU RECEPTEUR ACTIVE DE LA PROLIFERATION DES PEROXYSOMES (PPAR)

  摘要：

  本发明涉及一种具有式I的化合物，或其药学上可接受的盐、溶剂合物、水合物或立体异构体，该化合物在治疗或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中具有用途，如X综合征、2型糖尿病、高血糖、高脂血症、肥胖、凝血障碍、高血压、动脉硬化以及与X综合征和心血管疾病相关的其他疾病。

  公开号：

  WO2005019151A1
• 作为产物：
  描述：

  2-bromo-4-ethylanisole 在 盐酸 、 氢溴酸 、 magnesium 作用下， 反应 19.5h， 生成 (5-ethyl-2-hydroxy-phenyl)-pyridin-2-yl-methanone
  参考文献：
  名称：

  Antianaphylactic benzophenones and related compounds

  摘要：

  The synthesis and biological properties of 85 benzophenones and related compounds are described. The majority of the compounds inhibit the release of leukotrienes (LT) C4 and D4 in vitro from sensitized guinea pig chopped lung. In addition, some of the compounds inhibited the release of LTs from passively sensitized human chopped lung and protected guinea pigs from the effects of anaphylaxis in a modified Herxheimer test.

  DOI：

  10.1021/jm00391a010

文献信息

• Ppar modulators
  申请人：Gonzalez Valcarcel Isabel Cristina

  公开号：US20060257987A1

  公开（公告）日：2006-11-16

  The present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

  本发明涉及一种化合物I，或其药学上可接受的盐、溶剂化物、水合物或立体异构体，其在治疗或预防由过氧化物酶体增殖激活受体（PPAR）介导的疾病方面具有用途，例如X综合征、2型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉硬化以及其他与X综合征和心血管疾病有关的疾病。
• EVANS, DELME;CRACKNELL, MARK E.;SAUNDERS, JOHN C.;SMITH, CHRISTINE E.;WIL+, J. MED. CHEM., 30,(1987) N 8, 1321-1327
  作者：EVANS, DELME、CRACKNELL, MARK E.、SAUNDERS, JOHN C.、SMITH, CHRISTINE E.、WIL+

  DOI：——

  日期：——
• PPAR MODULATORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1660428A1

  公开（公告）日：2006-05-31
• [EN] PPAR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR ACTIVE DE LA PROLIFERATION DES PEROXYSOMES (PPAR)
  申请人：LILLY CO ELI

  公开号：WO2005019151A1

  公开（公告）日：2005-03-03

  The present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

  本发明涉及一种具有式I的化合物，或其药学上可接受的盐、溶剂合物、水合物或立体异构体，该化合物在治疗或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中具有用途，如X综合征、2型糖尿病、高血糖、高脂血症、肥胖、凝血障碍、高血压、动脉硬化以及与X综合征和心血管疾病相关的其他疾病。
• Antianaphylactic benzophenones and related compounds
  作者：Delme Evans、Mark E. Cracknell、John C. Saunders、Christine E. Smith、W. R. Nigel Williamson、William Dawson、W. John F. Sweatman

  DOI：10.1021/jm00391a010

  日期：1987.8

  The synthesis and biological properties of 85 benzophenones and related compounds are described. The majority of the compounds inhibit the release of leukotrienes (LT) C4 and D4 in vitro from sensitized guinea pig chopped lung. In addition, some of the compounds inhibited the release of LTs from passively sensitized human chopped lung and protected guinea pigs from the effects of anaphylaxis in a modified Herxheimer test.